Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis

Oncology Reports

Volumn 10, Issue 1, 2003, Pages 97-100

  Murata, Yoriko ^a   Ogawa, Yasuhiro ^a   Saibara, Toshiji ^a   Nishioka, Akihito ^a   Takeuchi, Naoko ^a   Kariya, Shinji ^a   Onishi, Saburo ^a   Yoshida, Shoji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Biopsy; Breast cancer; Computed tomography; Diagnosis; Liver; Non alcoholic steatohepatitis

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUOROURACIL; TAMOXIFEN;

ADULT; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FATTY LIVER; FEMALE; HUMAN; LIVER; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; SPLEEN; TOXIC HEPATITIS;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; FLUOROURACIL; HEPATITIS, TOXIC; HUMANS; LIVER; MIDDLE AGED; PROSPECTIVE STUDIES; SPLEEN; TAMOXIFEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0345181312     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.1.97     Document Type: Article

References (30)

1. Brunt EM: Non-alcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16, 2001.
2. James O and Day C: Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353: 1634-1636, 1999. (Pubitemid 29224514)
3. Wilcken NR: Tamoxifen hits the target in situ. Lancet 353: 1986-1987, 1999.
4. Ogawa Y, Nishioka A, Inomata T, Ohnishi T, Kariya S, Terashima M, Yoshida S, Tohchika N, Tanaka Y and Kumon M: Conservation treatment intensified with an anti-estrogen agent and CAF chemotherapy for stage I and II breast cancer. Oncol Rep 7: 479-484, 2000.
5. Ogawa Y, Nishioka A, Inomata T, Yokota N, Sasaki T, Terashima M, Yoshida S, Tanaka Y and Tohchika N: Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes. Oncol Rep 6: 801-805, 1999.
6. Ogawa Y, Nishioka A, Inomata T, Tsuboi N, Hayase N, Fukumoto M, Yoshida S, Tohchika N, Tanaka Y and Kumon M: Conservation treatment intensified with tamoxifen and CAF chemotherapy for subareolar breast cancers. Oncol Rep 5: 1337-1341, 1998. (Pubitemid 28474072)
7. Ogawa Y, Murata Y, Nishioka A, Inomata T and Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351: 725, 1998. (Pubitemid 28105346)
8. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S and Yoshida S: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7: 1299-1304, 2000.
9. Chitturi S and Farrell GC: Etiopathogenesis of non-alcoholic steatohepatitis. Semin Liver Dis 21: 27-41, 2001.
10. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR and MacSween RPM: Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353: 36-37, 1999. (Pubitemid 29037704)
11. Ludwig J, Viggiano TR, McGill DB and Ott B: Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980. (Pubitemid 10057164)
12. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, MacGill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP and Zinsmeister AR: The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 23: 1079-1083, 1996. (Pubitemid 26137050)
13. Garcia-Tsao G and Boyer JL: Outpatient liver biopsy: how safe is it? Ann Intern Med 118: 150-153, 1993.
14. Kato K, Takayama T, Katada N, Nishimura D, Shibata T, Kato K and Takeichi M: Evaluation of computed tomography in the diagnosis of liver disease. Acta Hepatol Jpn 21: 1340-1351, 1980.
15. Piekarski J, Goldberg HI, Royal SA, Axel L and Moss AA: Difference between liver and spleen CT numbers in the normal adults: its usefulness in predicting the presence of diffuse liver disease. Radiology 137: 727-729, 1984. (Pubitemid 11203707)
16. Kawata R, Sakata K, Kunieda T, Saji S, Doi H and Nozawa Y: Quantitative evaluation of fatty liver by computed tomography in rabbits. Am J Roentgenol 142: 741-746, 1984. (Pubitemid 14166603)
17. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CD, Slosman F and Rubesin SE: Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenol 171: 659-664, 1998. (Pubitemid 28406126)
18. Johnston RJ, Stamm ER, Lewin JM, Hendrick RE and Archer PG: Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen atenuation difference measurements. Abdom Imaging 23: 409-415, 1998. (Pubitemid 28304760)
19. Siegelman ES and Rosen MA: Imaging of hepatic steatosis. Semin Liver Dis 21: 71-80, 2001. (Pubitemid 32240487)
20. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, De Bernard B, Tiribelli C and Palma DL: Non-invasive in vitro quantitative assessment of fat content in human liver. J Hepatol 27: 108-113, 1997. (Pubitemid 27357063)
21. Nomura F, Ohnishi K, Ochiai T and Okuda K: Obesity-related non-alcoholic fatty liver: CT features and follow-up studies after low-calorie diet. Radiology 162: 845-847, 1987. (Pubitemid 17019225)
22. Chambers TP, Baron RL, Lush RM, Dodd GD and Miller WJ: Hepatic CT enhancement: comparison of ionic and non-ionic contrast agents in the same patients. Radiology 190: 721-725, 1994. (Pubitemid 24071037)
23. Day CP and James OFW: Steatohepatitis: a tale of two 'hits'. Gastroenterology 114: 842-845, 1998.
24. Teli MR, James OF, Burt AD, Bennett MK and Day CP: The natural history of non-alcoholic fatty liver. Hepatology 22: 1714-1719, 1995.
25. Caldwell SH, Oelsner DH, Lezzoli JC, Hespenheide EE, Battle EH and Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for undelying liver disease. Hepatology 29: 664-669, 1999. (Pubitemid 29109578)
26. Saibara T, Onishi S, Ogawa Y, Yoshida S and Enzan H: Bezafibrate for tamoxifen-induced fatty liver in breast cancer patients. Lancet 353: 1802, 1999.
27. Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M, Inomata T and Yoshida S: Toremifen-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 17: 1119-1123, 2000.
28. Gates GF and Dore EK: Streamline flow in the human portal vein. J Nucl Med 14: 79-83, 1973.
29. Arai K, Matsui O, Takahashi T, Ida M and Nishida Y: Focal spared areas in fatty liver caused by regional decreased portal flow. Am J Roentgenol 151: 300-302, 1988.
30. Matsui O, Takahashi S, Kadoya M, Yoshikawa J, Gabata T, Takashima T and Kitagawa K: Pseudolesions in segment IV of the liver at CT during arterial portography: correlation with abberant gastric venous drainage. Radiology 193: 31-35, 1994. (Pubitemid 24297993)